2025-03-11 03:33:19
Latest Post
NTPC Group to Invest Rs 96,000 Crore in Chhattisgarh
Arvind Fashions aims to expand its CLUB A stores across India
Somany Ceramics Elevates Luxury with the launch of Duragres 2025 Collection
Cosmo Films Bags SIES SOP Star Awards 2025 for Innovative Packaging Materials
Zaggle Prepaid Ocean Services Ltd receives 'Financial Institution of the Year' Award
Stock Report
Glenmark Life Sciences Ltd Q2FY23 PAT slips to Rs. 106.87 crores
Posted On : 2022-10-21 19:25:47( TIMEZONE : IST )
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 519.319 crores during the period ended September 30, 2022 as compared to Rs. 499.363 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 106.878 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 108.733 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 8.72 for the period ended September 30, 2022 as compared to Rs. 8.87 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 519.319 crs | ₹499.363 crs |  4.00% |
| Net Profit | ₹106.878 crs | ₹108.733 crs |  -1.71% |
| EPS | ₹8.72 | ₹8.87 | -1.69% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 519.319 crores during the period ended September 30, 2022 as compared to Rs.563.850 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.106.878 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.115.201 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.8.72 for the period ended September 30, 2022 as compared to Rs.9.82 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 519.319 crs | ₹563.850 crs | -7.90% |
| Net Profit | ₹106.878 crs | ₹115.201 crs | -7.22% |
| EPS | ₹8.72 | ₹9.82 | -11.20% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.1018.682 crores during the 6 Months period ended September 30, 2022 as compared to Rs.1092.733 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.215.611 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.216.114 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.17.60 for the 6 Months period ended September 30, 2022 as compared to Rs.19.19 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹1018.682 crs | ₹1092.733 crs | -6.78% |
| Net Profit | ₹215.611 crs | ₹216.114 crs | -0.23% |
| EPS | ₹17.60 | ₹19.19 | -8.29% |
Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 409.75 as compared to the previous close of Rs. 410.75. The total number of shares traded during the day was 3166 in over 518 trades.
The stock hit an intraday high of Rs. 410.50 and intraday low of 406.55. The net turnover during the day was Rs. 1295161.00.
